Previous 10 | Next 10 |
-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the firs...
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release first quarter 2022 financial results after the market closes on Thursday, May ...
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from its preclinical-stage IL-18 and LAG3-targeted IL-15 cytokine prog...
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on two novel XmAb ® cytokine programs at the American Ass...
Xencor, Inc. (XNCR) Q4 2021 Earnings Conference Call February 22, 2022, 17:00 ET Company Participants Charles Liles - Associate Director and Head, Corporate Communications & IR Bassil Dahiyat - Co-Founder, CEO, President & Director Allen Yang - SVP & Chief Medical Officer John Kuc...
Xencor press release (NASDAQ:XNCR): Q4 GAAP EPS of $1.21 beats by $1.11. Revenue of $154.02M (+268.0% Y/Y) beats by $77.73M. The company expects to have cash to fund research and development programs and operations through the end of 2025. Xencor expects to end 2022 with between $500M and $55...
-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the four...
AAN, ACA, OTCPK:ACLLF, AEM, AEVA, AGI, AHT, ALLO, ALR, AMED, ANSS, ARNA, AZUL, BAND, BBDC, BBWI, BCSF, BHP, BIRD, BKNG, BMA, BMRN, CCRN, CDEV, CHDN, CHK, CLOV, CMLS, CPE, CSV, CTRA, CW, DHC, DK, DKL, EBAY, EFC, OTCPK:EIFZF, EVH, EXR, FBRT, FIVN, FIX, FLGT, FLS, FNF, FRG, FTI, FUBO, GBT, GH, G...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that it will provide a corporate update and report financial results for th...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2022 corporate priorities and anticipated clinical development and research milestones. ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through ...
2024-06-04 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...